{"gene":"CD79A","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1988,"finding":"CD79A (mb-1/Ig-alpha) encodes a B-lineage-restricted membrane glycoprotein of 220 amino acids with a leader sequence, extracellular domain with two N-glycosylation sites, transmembrane domain, and cytoplasmic domain; antibodies against the protein stain the surface of pre-B and mature B cell lines but not T cell lines or fibroblasts, establishing it as a B-cell surface protein.","method":"cDNA cloning, nucleotide/amino acid sequence analysis, immunostaining with affinity-purified antibodies against fusion protein","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — original cloning and direct experimental characterization of protein expression by surface immunostaining, replicated across multiple cell lines","pmids":["2463161"],"is_preprint":false},{"year":1993,"finding":"Ig-alpha (CD79A) and Ig-beta form the signal-transduction module of the B cell antigen receptor; specific mutations in the IgM transmembrane domain that abrogate Ca2+ flux and phosphorylation responses also uncouple IgM from the Igα/Igβ heterodimer; fusion of the cytoplasmic domain of Igα to signaling-deficient IgM fully reconstitutes Ca2+ flux and phosphorylation, while fusion of Igβ alone restores only Ca2+ responses, demonstrating that Igα and Igβ are both necessary and sufficient for BCR signal transduction and can activate distinct signaling pathways.","method":"Mutagenesis of IgM transmembrane domain, cytoplasmic domain fusion constructs, Ca2+ flux assays, phosphorylation assays in B cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution experiments with domain-swap mutants and two orthogonal functional readouts (Ca2+ flux and phosphorylation)","pmids":["7688784"],"is_preprint":false},{"year":1992,"finding":"CD79A (mb-1) protein expression begins earlier than CD79B (B29) in B cell development: mb-1 is expressed in pre-B cells and persists through the plasma cell stage, whereas B29 expression begins later (from the pre-B/cytoplasmic-µ stage) and is absent from plasma cells, establishing differential regulation of the two BCR signaling components during B cell differentiation.","method":"Immunocytochemistry with anti-peptide antibodies on B cell lines and lymphoid tissue sections, analysis of acute lymphoblastic leukemia subtypes","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — immunostaining across multiple B cell differentiation stages and leukemia subtypes, single lab, one main method","pmids":["1396979"],"is_preprint":false},{"year":1995,"finding":"CD79A (mb-1/CD79a) is physically associated in the B cell membrane with immunoglobulin as part of the CD79 heterodimer (CD79a/CD79b), transmits signal after antigen binding, appears before the pre-B cell stage, and can persist at the plasma cell stage while CD79b is lost; it functions as the B cell equivalent of CD3.","method":"Immunohistochemistry with monoclonal antibody JCB117 on 454 paraffin-embedded tissue biopsies covering full range of B cell maturation stages","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — extensive immunohistochemical survey across diverse B cell maturation stages establishing expression pattern tied to functional BCR complex","pmids":["7632952"],"is_preprint":false},{"year":1999,"finding":"Homozygous loss-of-function splice mutation in CD79A (Igalpha) causes a complete block in B cell development at the pro-B to pre-B transition in humans, demonstrating that CD79A is required for progression through this checkpoint; comparison with mu-heavy-chain-deficient patients showed equivalent V-DJ rearrangement diversity, indicating CD79A does not play a critical role before co-expression with mu heavy chain as part of the pre-BCR.","method":"Genetic screening, immunofluorescence analysis of B cell developmental stages, V-DJ rearrangement sequencing in an agammaglobulinemia patient","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — human loss-of-function mutation with defined cellular phenotype and genetic epistasis comparison against mu-heavy-chain deficiency, replicated in second patient (PMID 11920841)","pmids":["10525050","11920841"],"is_preprint":false},{"year":2002,"finding":"Novel homozygous splice mutation (IVS2+1G>A) in CD79A causes B cell-deficient agammaglobulinemia in a second unrelated patient, confirming CD79A mutations as a cause of agammaglobulinemia.","method":"Genetic sequencing, clinical immunological evaluation","journal":"American journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — independent replication of loss-of-function phenotype in a second patient, single method (genetic sequencing plus immunological assessment)","pmids":["11920841"],"is_preprint":false},{"year":2003,"finding":"CD79A (mb1/Igalpha) undergoes somatic hypermutation (SHM) in germinal center and post-GC B cells, including normal peripheral B cells and malignant B cell lines; mutations are single nucleotide substitutions targeted to SHM hotspots, occurring at frequencies similar to other non-Ig SHM targets but lower than Ig genes, indicating CD79A is a substrate for the SHM machinery.","method":"Sequencing of CD79A/mb-1 loci in GC-derived malignant B cell lines and normal peripheral B cells; hotspot analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct sequencing across multiple cell types and lines, single lab, one primary method","pmids":["12651942"],"is_preprint":false},{"year":1995,"finding":"Alternative splicing of CD79A (Ig-alpha/mb-1) generates variant transcripts predicted to encode truncated proteins lacking a major portion of the extracellular Ig-like domain; these variants are present in multiple human B cell types detected by RNase protection assay.","method":"RNase protection assay, cDNA cloning, sequence analysis of variant transcripts from multiple B cell lines","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct detection of splice variants by RNase protection in multiple cell types, single lab","pmids":["7643857"],"is_preprint":false},{"year":1995,"finding":"A variant mb-1 transcript produced by alternative splicing encodes a protein that conserves the transmembrane and cytoplasmic portions but lacks extracellular cysteine residues required for disulfide bonds; transfection studies showed this variant mb-1 does not contribute to BCR surface expression; B cell activation (anti-IgM, LPS, or IL-4) induces significant increases in variant transcript levels.","method":"Alternative splicing characterization, transfection assays, B cell activation experiments with anti-IgM/LPS/IL-4","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — transfection reconstitution experiment showing functional null variant, combined with activation-regulated splicing, single lab","pmids":["8747711"],"is_preprint":false},{"year":2002,"finding":"Receptor-facilitated antigen presentation requires recruitment of the B cell linker protein (BLNK) to CD79A (Igalpha): non-ITAM tyrosines Y176 and Y204 of Igalpha, when mutated, divert BCR complexes to late endosomes but exclude them from vesicle lumena and prevent antigen presentation to T cells; phosphorylation of Y176/Y204 recruits BLNK, Vav, and Grb2; reconstitution with BLNK rescues antigen presentation and entry into the MHC class II compartment.","method":"Site-directed mutagenesis of Igalpha non-ITAM tyrosines (Y176/Y204), antigen presentation assays, subcellular trafficking analysis, reconstitution with BLNK","journal":"Journal of immunology (Baltimore, Md.: 1950)","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with functional reconstitution and subcellular localization readout, multiple orthogonal assays","pmids":["11859098"],"is_preprint":false},{"year":2006,"finding":"CD79A non-ITAM tyrosine Y204 becomes phosphorylated upon BCR engagement and mediates a distinct T cell-independent B cell activation pathway: knock-in mice with Y204F mutation show selective defects in T-independent B cell activation, proliferation, and antibody responses with reduced BLNK phosphorylation, Ca2+ flux, and NF-κB/JNK/ERK activation, while BCR capping, antigen internalization, antigen presentation, T cell-dependent responses, and Syk phosphorylation remain normal.","method":"Targeted knock-in mutagenesis (Y204F) in mice, B cell activation assays, proliferation assays, Ca2+ flux, kinase phosphorylation analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo knock-in mutagenesis with multiple orthogonal functional readouts establishing a specific signaling pathway","pmids":["16860757"],"is_preprint":false},{"year":2004,"finding":"Basal (ligand-independent, tonic) signals mediated through CD79A (Igalpha)/Igbeta cytoplasmic domains expressed as a membrane-targeted surrogate receptor in primary pro-B cells are sufficient to drive pre-BCR-dependent processes: enhanced proliferation at low IL-7, suppression of VH(D)JH recombination, and induction of kappa light chain recombination and expression, demonstrating that pre-BCR aggregation is not required for pre-BCR function.","method":"Surrogate receptor construct (membrane-targeted Igalpha/Igbeta cytoplasmic domains) introduced into primary pro-B cells by retroviral transduction; proliferation, VDJ recombination, and kappa chain expression assays","journal":"Journal of immunology (Baltimore, Md.: 1950)","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution approach with surrogate receptor in primary cells, multiple functional endpoints","pmids":["15240688"],"is_preprint":false},{"year":2006,"finding":"CD79A (Igalpha) tonic signaling through its ITAM and cytoplasmic domain supports development of follicular B cells; chimeric protein analysis with Tyr→Phe modifications and single vs. tandem ITAM copies showed both Igalpha and Igbeta support follicular B cell formation under tonic signaling conditions, but neither marginal zone nor B1 B cell subsets develop under purely tonic signal conditions.","method":"Chimeric receptor constructs with Tyr→Phe ITAM modifications, gene transfer into RAG2-/- pro-B cell lines and muMT mice, flow cytometric analysis of B cell subsets","journal":"Journal of immunology (Baltimore, Md.: 1950)","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis of ITAM tyrosines combined with in vivo gene transfer reconstitution and multi-subset analysis","pmids":["17114463"],"is_preprint":false},{"year":2010,"finding":"The CD79A (Igalpha) cytoplasmic domain is dominant over Igbeta for BCR internalization; the internalization signal is located in a region past the first cytoplasmic tyrosine (Y176); a 4-amino-acid motif within the Igalpha ITAM is sufficient to rescue aberrant internalization; each cytoplasmic domain alone is sufficient for trafficking to lysosomal compartments, but normal trafficking rate requires both Igalpha and Igbeta.","method":"Expression of Igalpha/Igbeta mutants in Igalpha/Igbeta-deficient murine lymphoid cell line, internalization assays, subcellular localization analysis","journal":"Immunology letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — domain mutagenesis with functional internalization and trafficking readouts, multiple orthogonal mutants tested","pmids":["20837062"],"is_preprint":false},{"year":2013,"finding":"IL-4 markedly upregulates Igα (CD79A) and Igβ protein (but not mRNA) expression in primary B cells via STAT6; elevated Igα/Igβ protein forms heterodimers that associate with IgM, promote IgM maturation and surface IgM expression, and result in amplified Lyn-dependent BCR signaling; in vivo pre-germinal center B cells show IL-4-dependent upregulation of Igα, Igβ, and surface IgM with elevated BCR-triggered phospho-ERK.","method":"IL-4 treatment of primary B cells, STAT6 requirement analysis, co-immunoprecipitation of heterodimers with IgM, surface IgM flow cytometry, BCR signaling assays, in vivo neutralization of IL-4","journal":"Journal of immunology (Baltimore, Md.: 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (co-IP, signaling assays, flow cytometry) in vitro and in vivo, with genetic validation (STAT6 requirement and anti-IL-4 neutralization)","pmids":["23776171"],"is_preprint":false},{"year":2013,"finding":"CD79A is unexpectedly expressed on immature bone marrow myeloid cells and is upregulated on myeloid-derived suppressor cells (MDSCs) in mouse models of metastatic cancer; crosslinking CD79A on MDSCs maintained their immature CD11b+Gr1+ phenotype, enhanced migration, increased T cell suppression, and increased pro-tumorigenic cytokine secretion (IL-6, CCL22); CD79A activation on myeloid cells signals through Syk, BLNK, ERK, and STAT3 phosphorylation.","method":"CD79A crosslinking with specific antibody on MDSCs, flow cytometry for phenotype, migration assays, T cell suppression assays, cytokine secretion measurement, phosphorylation analysis (Syk/BLNK/ERK/STAT3), in vivo tumor growth assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with crosslinking and signaling readouts, single lab, in vitro and in vivo","pmids":["24146823"],"is_preprint":false},{"year":2022,"finding":"CRISPR/Cas9 deletion of CD79A (or CD79B) in human B lymphoma cell lines causes loss of surface IgM expression in all tested lines by blocking N-glycan maturation and causing accumulation of immature BCR proteins, consistent with retention in the endoplasmic reticulum; rescue with wild-type CD79B restored surface CD79A and IgM with mature glycosylation, while a naturally occurring CD79B G137S mutant that disrupts CD79A/CD79B heterodimerization failed to rescue, demonstrating that CD79A/CD79B heterodimerization is required for BCR surface expression.","method":"CRISPR/Cas9 knockout of CD79A or CD79B in B lymphoma lines, rescue with WT vs. G137S mutant CD79B, N-glycan maturation analysis, surface IgM flow cytometry, ER retention assessment","journal":"Journal of immunology (Baltimore, Md.: 1950)","confidence":"High","confidence_rationale":"Tier 1 / Strong — CRISPR knockout with mechanistic rescue experiments using WT and heterodimerization-defective mutant, multiple cell lines, orthogonal assays","pmids":["36426942"],"is_preprint":false},{"year":2004,"finding":"In the avian (chicken) BCR, the cytoplasmic domain of Igalpha (CD79A ortholog) efficiently supports B cell development in precursors lacking endogenous surface Ig expression when expressed as a chimeric CD8α-Igalpha construct; by contrast, an equivalent chimeric construct containing the Igbeta cytoplasmic domain actively inhibited B cell development, demonstrating functionally distinct roles for the two cytoplasmic domains in B cell development.","method":"Retroviral gene transfer of chimeric CD8α-Igalpha or CD8α-Igbeta constructs into developing chicken B cell precursors in vivo; analysis of B cell development","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vivo reconstitution in avian model with chimeric constructs, single lab, ortholog study","pmids":["14962183"],"is_preprint":false},{"year":2007,"finding":"MHC class II associates with Igα/Igβ (CD79A/CD79B); mutations in the connecting peptide region of the MHC II alpha chain (but not beta chain) impair MHC II-mediated calcium mobilization and abolish co-association with Igα/Igβ, while Igβ knockdown by shRNA eliminates the MHC II-mediated calcium response but not cell death signaling.","method":"MHC II alpha chain connecting peptide mutagenesis, co-immunoprecipitation with Igα/Igβ, shRNA knockdown of Igβ, Ca2+ mobilization and cell death assays","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and mutagenesis combined with functional knockdown, single lab, two orthogonal approaches","pmids":["18194817"],"is_preprint":false},{"year":2021,"finding":"CD79A signaling domain incorporated as a composite CD79A/CD40 co-stimulatory endodomain in CD19 CAR-T cells enhances NF-κB and p38 activation upon CD19 antigen exposure, produces superior T cell proliferation, sustained tumor suppression, and enhanced in vivo anti-tumor activity and CAR-T cell expansion compared to CD28 or 4-1BB co-stimulatory domains in a Raji mouse model.","method":"Chimeric antigen receptor T cell engineering with CD79A/CD40 endodomain, NF-κB/p38 signaling analysis, in vitro co-culture cytotoxicity and proliferation assays, in vivo Raji xenograft mouse model","journal":"Molecular therapy: the journal of the American Society of Gene Therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — engineered receptor with signaling readouts and in vivo functional validation, single lab","pmids":["33940156"],"is_preprint":false}],"current_model":"CD79A (Igα/mb-1) is a B-lineage transmembrane glycoprotein that obligatorily heterodimerizes with CD79B (Igβ) to chaperone the B cell receptor (BCR) complex through the endoplasmic reticulum and onto the cell surface; within the BCR, its ITAM tyrosines recruit Syk to initiate signaling, while its non-ITAM tyrosines (Y176/Y204) independently recruit BLNK/Vav/Grb2 to mediate antigen internalization, antigen presentation, and T-independent B cell proliferation; CD79A also provides ligand-independent tonic signals required for B cell development through the pro-B to pre-B checkpoint, is regulated post-translationally by IL-4 via STAT6, undergoes somatic hypermutation in germinal center B cells, and loss-of-function mutations cause a complete block in B cell development resulting in agammaglobulinemia."},"narrative":{"mechanistic_narrative":"CD79A (Igα/mb-1) is a B-lineage-restricted transmembrane glycoprotein that serves as the signal-transduction component of the B cell antigen receptor (BCR), functioning as the B-cell equivalent of CD3 [PMID:2463161, PMID:7632952]. It obligatorily heterodimerizes with CD79B (Igβ), and this heterodimerization is required for maturation of BCR N-glycans, escape from the endoplasmic reticulum, and surface display of IgM; loss of either partner or a heterodimerization-defective CD79B mutant blocks surface BCR expression [PMID:36426942]. The Igα cytoplasmic domain is both necessary and sufficient to reconstitute Ca2+ flux and phosphorylation responses when fused to a signaling-deficient IgM, establishing it as a self-contained signaling module [PMID:7688784]. CD79A signaling is functionally partitioned: its ITAM tyrosines drive canonical activation, while the non-ITAM tyrosines Y176 and Y204 are phosphorylated upon BCR engagement and recruit BLNK, Vav, and Grb2 to mediate antigen internalization into the MHC class II compartment for presentation to T cells, and additionally support a distinct T-independent activation pathway feeding NF-κB/JNK/ERK signaling and proliferation [PMID:11859098, PMID:16860757]. The Igα cytoplasmic domain is dominant over Igβ for BCR internalization and lysosomal trafficking [PMID:20837062]. Beyond antigen-driven signaling, ligand-independent tonic signals through the Igα/Igβ cytoplasmic domains drive pre-BCR-dependent processes—proliferation, suppression of VH(D)JH recombination, and induction of kappa light chain expression—and support follicular B cell development [PMID:15240688, PMID:17114463]. Consistent with this central role, homozygous loss-of-function mutations in CD79A cause a complete block in B cell development at the pro-B to pre-B transition, producing agammaglobulinemia [PMID:10525050, PMID:11920841]. CD79A expression and signaling are further tuned by IL-4, which upregulates Igα/Igβ protein via STAT6 to amplify surface IgM and BCR signaling [PMID:23776171].","teleology":[{"year":1988,"claim":"Established the molecular identity of CD79A by cloning a B-lineage-restricted surface glycoprotein, defining the entity before any signaling role was known.","evidence":"cDNA cloning, sequence analysis, and surface immunostaining across B and non-B cell lines","pmids":["2463161"],"confidence":"High","gaps":["No functional or signaling role assigned at cloning","Partner CD79B and BCR association not yet defined"]},{"year":1992,"claim":"Resolved the developmental timing of CD79A relative to CD79B, showing the two BCR signaling components are differentially regulated across B cell differentiation.","evidence":"Immunocytochemistry with anti-peptide antibodies on B cell lines, tissues, and leukemias","pmids":["1396979"],"confidence":"Medium","gaps":["Expression timing does not establish signaling function","Single primary method"]},{"year":1993,"claim":"Demonstrated that the Igα cytoplasmic domain is necessary and sufficient for BCR signal transduction, defining CD79A as the receptor's signaling module rather than a passive structural subunit.","evidence":"IgM transmembrane mutagenesis and Igα/Igβ cytoplasmic-domain fusion constructs with Ca2+ flux and phosphorylation readouts","pmids":["7688784"],"confidence":"High","gaps":["Downstream effectors of distinct Igα vs Igβ pathways not enumerated","In vitro/cell-line context only"]},{"year":1995,"claim":"Characterized alternatively spliced CD79A transcripts encoding truncated proteins, including a variant lacking extracellular disulfide cysteines that does not support BCR surface expression and is induced by B cell activation.","evidence":"RNase protection, cDNA cloning, transfection reconstitution, and anti-IgM/LPS/IL-4 activation assays","pmids":["7643857","8747711"],"confidence":"Medium","gaps":["Physiological role of activation-induced variant unresolved","Whether variant acts as a dominant-negative not tested"]},{"year":1999,"claim":"Identified CD79A as genetically required for the pro-B to pre-B checkpoint in humans, linking the BCR signaling module to a defined developmental block and to agammaglobulinemia.","evidence":"Genetic screening, B cell developmental immunofluorescence, and V-DJ sequencing in agammaglobulinemia patients, replicated in a second patient","pmids":["10525050","11920841"],"confidence":"High","gaps":["Molecular signal that arrests development not defined","Epistasis only relative to mu-heavy-chain deficiency"]},{"year":2002,"claim":"Confirmed CD79A loss-of-function as a recurrent cause of agammaglobulinemia in an independent patient, solidifying genotype-phenotype causality.","evidence":"Genetic sequencing and clinical immunological evaluation","pmids":["11920841"],"confidence":"Medium","gaps":["Single method","No functional reconstitution of the specific splice mutation"]},{"year":2002,"claim":"Defined the non-ITAM tyrosines Y176/Y204 as the adaptor-recruitment platform that routes the BCR for antigen presentation, separating presentation from canonical activation.","evidence":"Site-directed mutagenesis of Y176/Y204, BLNK reconstitution, antigen presentation and subcellular trafficking assays","pmids":["11859098"],"confidence":"High","gaps":["Relative contribution of Vav vs Grb2 not dissected","Structural basis of phospho-tyrosine recognition not resolved"]},{"year":2004,"claim":"Showed that ligand-independent tonic signals from the Igα/Igβ cytoplasmic domains alone are sufficient for pre-BCR functions, establishing that receptor aggregation is dispensable for these outputs.","evidence":"Membrane-targeted surrogate Igα/Igβ receptor in primary pro-B cells with proliferation, VDJ recombination, and kappa expression readouts; chicken chimeric CD8α-Igα reconstitution","pmids":["15240688","14962183"],"confidence":"High","gaps":["Source of tonic signal initiation unknown","Igα and Igβ shown to have opposing effects on development in avian model, mechanism unresolved"]},{"year":2006,"claim":"Assigned distinct in vivo functions to Igα tyrosine motifs—Y204 to T-independent activation and the ITAM/cytoplasmic domain to follicular B cell development—demonstrating signal partitioning within a single chain.","evidence":"Y204F knock-in mice and chimeric ITAM Tyr→Phe constructs with activation, proliferation, Ca2+, kinase, and B cell subset analyses","pmids":["16860757","17114463"],"confidence":"High","gaps":["Why marginal zone and B1 subsets fail to form under tonic signaling not explained","Direct binding partners of Y204 not all defined"]},{"year":2007,"claim":"Linked CD79A/CD79B to MHC class II signaling, showing Igα/Igβ co-associate with MHC II to mediate calcium responses.","evidence":"MHC II alpha-chain connecting-peptide mutagenesis, co-IP with Igα/Igβ, and Igβ shRNA knockdown with Ca2+ and cell-death readouts","pmids":["18194817"],"confidence":"Medium","gaps":["Direct vs indirect association of CD79A specifically not isolated from Igβ","Physiological role of MHC II–BCR module unclear"]},{"year":2010,"claim":"Mapped the BCR internalization signal to the Igα cytoplasmic domain, showing it is dominant over Igβ for endocytosis and lysosomal trafficking.","evidence":"Igα/Igβ mutant expression in deficient murine lymphoid cells with internalization and subcellular localization assays","pmids":["20837062"],"confidence":"High","gaps":["Endocytic adaptors engaged by the internalization motif not identified","Cell-line context only"]},{"year":2013,"claim":"Established post-translational control of CD79A by IL-4/STAT6 and uncovered an unexpected non-B-cell role on myeloid-derived suppressor cells.","evidence":"IL-4 treatment with STAT6 dependence, co-IP and signaling assays in primary B cells; CD79A crosslinking with Syk/BLNK/ERK/STAT3 readouts and tumor assays on MDSCs","pmids":["23776171","24146823"],"confidence":"Medium","gaps":["Mechanism of CD79A surface display on myeloid cells without a conventional BCR unknown","Myeloid finding from single lab"]},{"year":2022,"claim":"Defined the chaperone mechanism: CD79A/CD79B heterodimerization is required for N-glycan maturation and ER export of the BCR, explaining why either subunit's loss abolishes surface IgM.","evidence":"CRISPR/Cas9 knockout in B lymphoma lines with WT vs heterodimerization-defective CD79B G137S rescue, N-glycan maturation and surface IgM analyses","pmids":["36426942"],"confidence":"High","gaps":["Step at which immature BCR is retained in ER not resolved at structural level","Whether human developmental block reflects same trafficking defect not directly tested"]},{"year":2021,"claim":"Demonstrated translational utility of the CD79A signaling domain as a CAR-T co-stimulatory endodomain, leveraging its NF-κB/p38 activation.","evidence":"CD79A/CD40 composite endodomain in CD19 CAR-T cells with signaling, cytotoxicity, and Raji xenograft assays","pmids":["33940156"],"confidence":"Medium","gaps":["Engineered context does not test endogenous CD79A function","Single lab"]},{"year":null,"claim":"How CD79A signaling is repurposed on non-B myeloid cells lacking a conventional BCR, and the structural basis for its differential ITAM vs non-ITAM tyrosine partner selection, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of CD79A in complex with downstream adaptors in the corpus","Mechanism of CD79A surface expression on myeloid cells unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,9,10]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[9,10]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[9,13]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,16]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[16]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,10,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,9,10]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,11,12]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[16,14]}],"complexes":["B cell antigen receptor (BCR) complex","CD79A/CD79B heterodimer"],"partners":["CD79B","BLNK","VAV","GRB2","SYK","IGM","LYN","STAT6"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11912","full_name":"B-cell antigen receptor complex-associated protein alpha chain","aliases":["Ig-alpha","MB-1 membrane glycoprotein","Membrane-bound immunoglobulin-associated protein","Surface IgM-associated protein"],"length_aa":226,"mass_kda":25.0,"function":"Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B-cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P11912/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD79A","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD79A","total_profiled":1310},"omim":[{"mim_id":"613501","title":"AGAMMAGLOBULINEMIA 3, AUTOSOMAL RECESSIVE; AGM3","url":"https://www.omim.org/entry/613501"},{"mim_id":"612692","title":"AGAMMAGLOBULINEMIA 6, AUTOSOMAL RECESSIVE; AGM6","url":"https://www.omim.org/entry/612692"},{"mim_id":"605300","title":"SH2B ADAPTOR PROTEIN 2; SH2B2","url":"https://www.omim.org/entry/605300"},{"mim_id":"605027","title":"LYMPHOMA, NON-HODGKIN, FAMILIAL","url":"https://www.omim.org/entry/605027"},{"mim_id":"604762","title":"SWITCH-ASSOCIATED PROTEIN 70","url":"https://www.omim.org/entry/604762"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":157.7},{"tissue":"lymphoid tissue","ntpm":510.4}],"url":"https://www.proteinatlas.org/search/CD79A"},"hgnc":{"alias_symbol":["MB-1","Ig-alpha","MB1","IGAlpha"],"prev_symbol":["IGA"]},"alphafold":{"accession":"P11912","domains":[{"cath_id":"2.60.40.10","chopping":"42-127","consensus_level":"high","plddt":89.6981,"start":42,"end":127},{"cath_id":"1.20.5","chopping":"132-187","consensus_level":"medium","plddt":84.4534,"start":132,"end":187}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11912","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11912-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11912-F1-predicted_aligned_error_v6.png","plddt_mean":77.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD79A","jax_strain_url":"https://www.jax.org/strain/search?query=CD79A"},"sequence":{"accession":"P11912","fasta_url":"https://rest.uniprot.org/uniprotkb/P11912.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11912/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11912"}},"corpus_meta":[{"pmid":"21949093","id":"PMC_21949093","title":"The pathophysiology of IgA nephropathy.","date":"2011","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/21949093","citation_count":694,"is_preprint":false},{"pmid":"12524384","id":"PMC_12524384","title":"IgA Fc receptors.","date":"2001","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12524384","citation_count":391,"is_preprint":false},{"pmid":"20101521","id":"PMC_20101521","title":"Selective IgA deficiency.","date":"2010","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20101521","citation_count":366,"is_preprint":false},{"pmid":"2463161","id":"PMC_2463161","title":"B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties.","date":"1988","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2463161","citation_count":295,"is_preprint":false},{"pmid":"11576875","id":"PMC_11576875","title":"Predicting progression in IgA nephropathy.","date":"2001","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/11576875","citation_count":292,"is_preprint":false},{"pmid":"30134201","id":"PMC_30134201","title":"IgA Responses to Microbiota.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30134201","citation_count":269,"is_preprint":false},{"pmid":"4601708","id":"PMC_4601708","title":"IgA nephropathy.","date":"1974","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/4601708","citation_count":256,"is_preprint":false},{"pmid":"11274926","id":"PMC_11274926","title":"IgA and the IgA Fc receptor.","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11274926","citation_count":221,"is_preprint":false},{"pmid":"3871459","id":"PMC_3871459","title":"Jacalin: an IgA-binding lectin.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3871459","citation_count":215,"is_preprint":false},{"pmid":"7688784","id":"PMC_7688784","title":"Signal transduction by immunoglobulin is mediated through Ig alpha and Ig beta.","date":"1993","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7688784","citation_count":205,"is_preprint":false},{"pmid":"31817406","id":"PMC_31817406","title":"IgA: Structure, Function, and Developability.","date":"2019","source":"Antibodies (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31817406","citation_count":200,"is_preprint":false},{"pmid":"22430056","id":"PMC_22430056","title":"Pathogenesis of IgA nephropathy.","date":"2012","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/22430056","citation_count":185,"is_preprint":false},{"pmid":"24892706","id":"PMC_24892706","title":"The genetics and immunobiology of IgA nephropathy.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24892706","citation_count":175,"is_preprint":false},{"pmid":"38036542","id":"PMC_38036542","title":"IgA nephropathy.","date":"2023","source":"Nature reviews. Disease primers","url":"https://pubmed.ncbi.nlm.nih.gov/38036542","citation_count":167,"is_preprint":false},{"pmid":"7632952","id":"PMC_7632952","title":"CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7632952","citation_count":151,"is_preprint":false},{"pmid":"10525050","id":"PMC_10525050","title":"Mutations in Igalpha (CD79a) result in a complete block in B-cell development.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10525050","citation_count":147,"is_preprint":false},{"pmid":"22539830","id":"PMC_22539830","title":"Corticosteroid therapy in IgA nephropathy.","date":"2012","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22539830","citation_count":142,"is_preprint":false},{"pmid":"3142256","id":"PMC_3142256","title":"The immunohistology of IgA nephropathy.","date":"1988","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/3142256","citation_count":135,"is_preprint":false},{"pmid":"34170395","id":"PMC_34170395","title":"IgA vasculitis.","date":"2021","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/34170395","citation_count":120,"is_preprint":false},{"pmid":"34495361","id":"PMC_34495361","title":"Current treatment of IgA nephropathy.","date":"2021","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/34495361","citation_count":116,"is_preprint":false},{"pmid":"16641928","id":"PMC_16641928","title":"Treatment of IgA nephropathy.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16641928","citation_count":112,"is_preprint":false},{"pmid":"12110007","id":"PMC_12110007","title":"Interactions of human mesangial cells with IgA and IgA-containing immune complexes.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12110007","citation_count":109,"is_preprint":false},{"pmid":"12651942","id":"PMC_12651942","title":"Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12651942","citation_count":106,"is_preprint":false},{"pmid":"11235901","id":"PMC_11235901","title":"Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.","date":"2001","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/11235901","citation_count":106,"is_preprint":false},{"pmid":"25116102","id":"PMC_25116102","title":"IgA, IgA receptors, and their anti-inflammatory properties.","date":"2014","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25116102","citation_count":105,"is_preprint":false},{"pmid":"29360814","id":"PMC_29360814","title":"Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.","date":"2018","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29360814","citation_count":104,"is_preprint":false},{"pmid":"3610212","id":"PMC_3610212","title":"IgA- and secretory IgA-opsonized S. aureus induce a respiratory burst and phagocytosis by polymorphonuclear leucocytes.","date":"1987","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3610212","citation_count":103,"is_preprint":false},{"pmid":"15156526","id":"PMC_15156526","title":"Pathogenesis of IgA nephropathy.","date":"2004","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/15156526","citation_count":100,"is_preprint":false},{"pmid":"34379175","id":"PMC_34379175","title":"Complement activation in IgA nephropathy.","date":"2021","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/34379175","citation_count":92,"is_preprint":false},{"pmid":"3367561","id":"PMC_3367561","title":"Proteinuria in IgA nephropathy.","date":"1988","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/3367561","citation_count":88,"is_preprint":false},{"pmid":"25483334","id":"PMC_25483334","title":"Re-thinking the functions of IgA(+) plasma cells.","date":"2014","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/25483334","citation_count":88,"is_preprint":false},{"pmid":"15202611","id":"PMC_15202611","title":"IgA nephropathy: an update.","date":"2004","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15202611","citation_count":81,"is_preprint":false},{"pmid":"1931006","id":"PMC_1931006","title":"IgA deficiency.","date":"1991","source":"Immunodeficiency reviews","url":"https://pubmed.ncbi.nlm.nih.gov/1931006","citation_count":80,"is_preprint":false},{"pmid":"9924428","id":"PMC_9924428","title":"Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.","date":"1998","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9924428","citation_count":79,"is_preprint":false},{"pmid":"39460694","id":"PMC_39460694","title":"Atrasentan in Patients with IgA Nephropathy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39460694","citation_count":74,"is_preprint":false},{"pmid":"38203179","id":"PMC_38203179","title":"B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38203179","citation_count":66,"is_preprint":false},{"pmid":"19834792","id":"PMC_19834792","title":"Role of IgA and IgA fc receptors in inflammation.","date":"2009","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19834792","citation_count":66,"is_preprint":false},{"pmid":"1396979","id":"PMC_1396979","title":"The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation.","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1396979","citation_count":66,"is_preprint":false},{"pmid":"1287121","id":"PMC_1287121","title":"Receptors for IgA on phagocytic cells.","date":"1992","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/1287121","citation_count":64,"is_preprint":false},{"pmid":"10912936","id":"PMC_10912936","title":"Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.","date":"2000","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/10912936","citation_count":63,"is_preprint":false},{"pmid":"24709842","id":"PMC_24709842","title":"MicroRNAs in IgA nephropathy.","date":"2014","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/24709842","citation_count":61,"is_preprint":false},{"pmid":"21679872","id":"PMC_21679872","title":"IgA pemphigus.","date":"2011","source":"Clinics in dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21679872","citation_count":60,"is_preprint":false},{"pmid":"12133959","id":"PMC_12133959","title":"Isolation and detection of human IgA using a streptococcal IgA-binding peptide.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12133959","citation_count":60,"is_preprint":false},{"pmid":"12383768","id":"PMC_12383768","title":"Pathogenic significance of IgA receptor interactions in IgA nephropathy.","date":"2002","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12383768","citation_count":59,"is_preprint":false},{"pmid":"26567162","id":"PMC_26567162","title":"Role of complement in IgA nephropathy.","date":"2015","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/26567162","citation_count":58,"is_preprint":false},{"pmid":"24146823","id":"PMC_24146823","title":"Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24146823","citation_count":58,"is_preprint":false},{"pmid":"7520411","id":"PMC_7520411","title":"The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.","date":"1994","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/7520411","citation_count":56,"is_preprint":false},{"pmid":"34183391","id":"PMC_34183391","title":"IgA potentiates NETosis in response to viral infection.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34183391","citation_count":53,"is_preprint":false},{"pmid":"3055972","id":"PMC_3055972","title":"Activation of complement in IgA nephropathy.","date":"1988","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/3055972","citation_count":52,"is_preprint":false},{"pmid":"38053977","id":"PMC_38053977","title":"Targeting complement in IgA nephropathy.","date":"2023","source":"Clinical kidney journal","url":"https://pubmed.ncbi.nlm.nih.gov/38053977","citation_count":51,"is_preprint":false},{"pmid":"37114051","id":"PMC_37114051","title":"Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37114051","citation_count":51,"is_preprint":false},{"pmid":"18222347","id":"PMC_18222347","title":"The role of secretory IgA and complement in IgA nephropathy.","date":"2008","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/18222347","citation_count":51,"is_preprint":false},{"pmid":"16860757","id":"PMC_16860757","title":"The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igalpha cytoplasmic domain.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16860757","citation_count":49,"is_preprint":false},{"pmid":"7887454","id":"PMC_7887454","title":"Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas.","date":"1995","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7887454","citation_count":48,"is_preprint":false},{"pmid":"28293726","id":"PMC_28293726","title":"Inflammation in IgA nephropathy.","date":"2017","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/28293726","citation_count":47,"is_preprint":false},{"pmid":"18222350","id":"PMC_18222350","title":"The glomerular response to IgA deposition in IgA nephropathy.","date":"2008","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/18222350","citation_count":46,"is_preprint":false},{"pmid":"31812619","id":"PMC_31812619","title":"IgA pemphigus: A systematic review.","date":"2019","source":"Journal of the American Academy of Dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/31812619","citation_count":45,"is_preprint":false},{"pmid":"36426942","id":"PMC_36426942","title":"Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.","date":"2022","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/36426942","citation_count":45,"is_preprint":false},{"pmid":"2205751","id":"PMC_2205751","title":"Polymeric IgA and immune complex concentrations in IgA-related renal disease.","date":"1990","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/2205751","citation_count":43,"is_preprint":false},{"pmid":"10874883","id":"PMC_10874883","title":"Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias.","date":"2000","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10874883","citation_count":41,"is_preprint":false},{"pmid":"11840384","id":"PMC_11840384","title":"CD44 expression in IgA nephropathy.","date":"2002","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/11840384","citation_count":41,"is_preprint":false},{"pmid":"18838917","id":"PMC_18838917","title":"Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.","date":"2009","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/18838917","citation_count":41,"is_preprint":false},{"pmid":"10411380","id":"PMC_10411380","title":"Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role.","date":"1999","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/10411380","citation_count":40,"is_preprint":false},{"pmid":"16026297","id":"PMC_16026297","title":"Secretory IgA antibodies from plants.","date":"2005","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/16026297","citation_count":39,"is_preprint":false},{"pmid":"20500772","id":"PMC_20500772","title":"IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis.","date":"2010","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20500772","citation_count":39,"is_preprint":false},{"pmid":"9341762","id":"PMC_9341762","title":"Size-dependent effect of IgA on the IgA Fc receptor (CD89).","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9341762","citation_count":39,"is_preprint":false},{"pmid":"11920841","id":"PMC_11920841","title":"Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia.","date":"2002","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11920841","citation_count":37,"is_preprint":false},{"pmid":"7643857","id":"PMC_7643857","title":"Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79b (Ig-beta/B29) RNA transcripts in human B cells.","date":"1995","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7643857","citation_count":37,"is_preprint":false},{"pmid":"39188719","id":"PMC_39188719","title":"Contemporary review of IgA nephropathy.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39188719","citation_count":36,"is_preprint":false},{"pmid":"33940156","id":"PMC_33940156","title":"Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.","date":"2021","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33940156","citation_count":35,"is_preprint":false},{"pmid":"10392257","id":"PMC_10392257","title":"Pathogenesis of IgA nephropathy.","date":"1999","source":"Annales de medecine interne","url":"https://pubmed.ncbi.nlm.nih.gov/10392257","citation_count":34,"is_preprint":false},{"pmid":"856715","id":"PMC_856715","title":"IgA nephropathy.","date":"1977","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/856715","citation_count":33,"is_preprint":false},{"pmid":"11859098","id":"PMC_11859098","title":"Receptor-facilitated antigen presentation requires the recruitment of B cell linker protein to Igalpha.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11859098","citation_count":33,"is_preprint":false},{"pmid":"23269075","id":"PMC_23269075","title":"IgA production and tonsillar focal infection in IgA nephropathy.","date":"2012","source":"Journal of clinical and experimental hematopathology : JCEH","url":"https://pubmed.ncbi.nlm.nih.gov/23269075","citation_count":33,"is_preprint":false},{"pmid":"26572664","id":"PMC_26572664","title":"Role of IgA receptors in the pathogenesis of IgA nephropathy.","date":"2015","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/26572664","citation_count":33,"is_preprint":false},{"pmid":"8454258","id":"PMC_8454258","title":"Expression of the Ig-associated heterodimer (mb-1 and B29) in Hodgkin's disease.","date":"1993","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/8454258","citation_count":33,"is_preprint":false},{"pmid":"12115880","id":"PMC_12115880","title":"Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias.","date":"2002","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12115880","citation_count":32,"is_preprint":false},{"pmid":"32085673","id":"PMC_32085673","title":"Immunological Pattern in IgA Nephropathy.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32085673","citation_count":31,"is_preprint":false},{"pmid":"16005710","id":"PMC_16005710","title":"Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.","date":"2005","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16005710","citation_count":31,"is_preprint":false},{"pmid":"23776171","id":"PMC_23776171","title":"IL-4 upregulates Igα and Igβ protein, resulting in augmented IgM maturation and B cell receptor-triggered B cell activation.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23776171","citation_count":30,"is_preprint":false},{"pmid":"29178575","id":"PMC_29178575","title":"Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy.","date":"2018","source":"Pediatrics international : official journal of the Japan Pediatric Society","url":"https://pubmed.ncbi.nlm.nih.gov/29178575","citation_count":30,"is_preprint":false},{"pmid":"35577505","id":"PMC_35577505","title":"Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35577505","citation_count":30,"is_preprint":false},{"pmid":"15752226","id":"PMC_15752226","title":"Mechanisms of tubulointerstitial injury in IgA nephropathy.","date":"2005","source":"Kidney international. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/15752226","citation_count":30,"is_preprint":false},{"pmid":"12366855","id":"PMC_12366855","title":"Salivary IgA subclasses and bacteria-reactive IgA in patients with aggressive periodontitis.","date":"2002","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/12366855","citation_count":30,"is_preprint":false},{"pmid":"20606479","id":"PMC_20606479","title":"Oxidative stress in IgA nephropathy.","date":"2010","source":"Nephron. Clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/20606479","citation_count":28,"is_preprint":false},{"pmid":"14631563","id":"PMC_14631563","title":"Pathogenesis of IgA nephropathy.","date":"2003","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/14631563","citation_count":27,"is_preprint":false},{"pmid":"15240688","id":"PMC_15240688","title":"Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15240688","citation_count":24,"is_preprint":false},{"pmid":"36469024","id":"PMC_36469024","title":"Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36469024","citation_count":23,"is_preprint":false},{"pmid":"8747711","id":"PMC_8747711","title":"The novel variants of mb-1 and B29 transcripts generated by alternative mRNA splicing.","date":"1995","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/8747711","citation_count":23,"is_preprint":false},{"pmid":"9367406","id":"PMC_9367406","title":"IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells.","date":"1997","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9367406","citation_count":23,"is_preprint":false},{"pmid":"34664087","id":"PMC_34664087","title":"The microbiome and IgA nephropathy.","date":"2021","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/34664087","citation_count":22,"is_preprint":false},{"pmid":"10493564","id":"PMC_10493564","title":"Familial IgA nephropathy.","date":"1999","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/10493564","citation_count":22,"is_preprint":false},{"pmid":"20837062","id":"PMC_20837062","title":"The role of Ig-α/β in B cell antigen receptor internalization.","date":"2010","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/20837062","citation_count":22,"is_preprint":false},{"pmid":"18194817","id":"PMC_18194817","title":"MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death.","date":"2007","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/18194817","citation_count":22,"is_preprint":false},{"pmid":"14962183","id":"PMC_14962183","title":"The avian B-cell receptor complex: distinct roles of Igalpha and Igbeta in B-cell development.","date":"2004","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/14962183","citation_count":21,"is_preprint":false},{"pmid":"17114463","id":"PMC_17114463","title":"Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17114463","citation_count":21,"is_preprint":false},{"pmid":"8656670","id":"PMC_8656670","title":"Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8656670","citation_count":21,"is_preprint":false},{"pmid":"32553243","id":"PMC_32553243","title":"Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy.","date":"2020","source":"Advances in chronic kidney disease","url":"https://pubmed.ncbi.nlm.nih.gov/32553243","citation_count":21,"is_preprint":false},{"pmid":"35125382","id":"PMC_35125382","title":"IgA vasculitis nephritis.","date":"2022","source":"Current opinion in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/35125382","citation_count":19,"is_preprint":false},{"pmid":"35172987","id":"PMC_35172987","title":"Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy.","date":"2022","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/35172987","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46153,"output_tokens":5578,"usd":0.111064,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14311,"output_tokens":4589,"usd":0.09314,"stage2_stop_reason":"end_turn"},"total_usd":0.204204,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"CD79A (mb-1/Ig-alpha) encodes a B-lineage-restricted membrane glycoprotein of 220 amino acids with a leader sequence, extracellular domain with two N-glycosylation sites, transmembrane domain, and cytoplasmic domain; antibodies against the protein stain the surface of pre-B and mature B cell lines but not T cell lines or fibroblasts, establishing it as a B-cell surface protein.\",\n      \"method\": \"cDNA cloning, nucleotide/amino acid sequence analysis, immunostaining with affinity-purified antibodies against fusion protein\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original cloning and direct experimental characterization of protein expression by surface immunostaining, replicated across multiple cell lines\",\n      \"pmids\": [\"2463161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Ig-alpha (CD79A) and Ig-beta form the signal-transduction module of the B cell antigen receptor; specific mutations in the IgM transmembrane domain that abrogate Ca2+ flux and phosphorylation responses also uncouple IgM from the Igα/Igβ heterodimer; fusion of the cytoplasmic domain of Igα to signaling-deficient IgM fully reconstitutes Ca2+ flux and phosphorylation, while fusion of Igβ alone restores only Ca2+ responses, demonstrating that Igα and Igβ are both necessary and sufficient for BCR signal transduction and can activate distinct signaling pathways.\",\n      \"method\": \"Mutagenesis of IgM transmembrane domain, cytoplasmic domain fusion constructs, Ca2+ flux assays, phosphorylation assays in B cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution experiments with domain-swap mutants and two orthogonal functional readouts (Ca2+ flux and phosphorylation)\",\n      \"pmids\": [\"7688784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD79A (mb-1) protein expression begins earlier than CD79B (B29) in B cell development: mb-1 is expressed in pre-B cells and persists through the plasma cell stage, whereas B29 expression begins later (from the pre-B/cytoplasmic-µ stage) and is absent from plasma cells, establishing differential regulation of the two BCR signaling components during B cell differentiation.\",\n      \"method\": \"Immunocytochemistry with anti-peptide antibodies on B cell lines and lymphoid tissue sections, analysis of acute lymphoblastic leukemia subtypes\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — immunostaining across multiple B cell differentiation stages and leukemia subtypes, single lab, one main method\",\n      \"pmids\": [\"1396979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CD79A (mb-1/CD79a) is physically associated in the B cell membrane with immunoglobulin as part of the CD79 heterodimer (CD79a/CD79b), transmits signal after antigen binding, appears before the pre-B cell stage, and can persist at the plasma cell stage while CD79b is lost; it functions as the B cell equivalent of CD3.\",\n      \"method\": \"Immunohistochemistry with monoclonal antibody JCB117 on 454 paraffin-embedded tissue biopsies covering full range of B cell maturation stages\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — extensive immunohistochemical survey across diverse B cell maturation stages establishing expression pattern tied to functional BCR complex\",\n      \"pmids\": [\"7632952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Homozygous loss-of-function splice mutation in CD79A (Igalpha) causes a complete block in B cell development at the pro-B to pre-B transition in humans, demonstrating that CD79A is required for progression through this checkpoint; comparison with mu-heavy-chain-deficient patients showed equivalent V-DJ rearrangement diversity, indicating CD79A does not play a critical role before co-expression with mu heavy chain as part of the pre-BCR.\",\n      \"method\": \"Genetic screening, immunofluorescence analysis of B cell developmental stages, V-DJ rearrangement sequencing in an agammaglobulinemia patient\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human loss-of-function mutation with defined cellular phenotype and genetic epistasis comparison against mu-heavy-chain deficiency, replicated in second patient (PMID 11920841)\",\n      \"pmids\": [\"10525050\", \"11920841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Novel homozygous splice mutation (IVS2+1G>A) in CD79A causes B cell-deficient agammaglobulinemia in a second unrelated patient, confirming CD79A mutations as a cause of agammaglobulinemia.\",\n      \"method\": \"Genetic sequencing, clinical immunological evaluation\",\n      \"journal\": \"American journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — independent replication of loss-of-function phenotype in a second patient, single method (genetic sequencing plus immunological assessment)\",\n      \"pmids\": [\"11920841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD79A (mb1/Igalpha) undergoes somatic hypermutation (SHM) in germinal center and post-GC B cells, including normal peripheral B cells and malignant B cell lines; mutations are single nucleotide substitutions targeted to SHM hotspots, occurring at frequencies similar to other non-Ig SHM targets but lower than Ig genes, indicating CD79A is a substrate for the SHM machinery.\",\n      \"method\": \"Sequencing of CD79A/mb-1 loci in GC-derived malignant B cell lines and normal peripheral B cells; hotspot analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct sequencing across multiple cell types and lines, single lab, one primary method\",\n      \"pmids\": [\"12651942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Alternative splicing of CD79A (Ig-alpha/mb-1) generates variant transcripts predicted to encode truncated proteins lacking a major portion of the extracellular Ig-like domain; these variants are present in multiple human B cell types detected by RNase protection assay.\",\n      \"method\": \"RNase protection assay, cDNA cloning, sequence analysis of variant transcripts from multiple B cell lines\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct detection of splice variants by RNase protection in multiple cell types, single lab\",\n      \"pmids\": [\"7643857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A variant mb-1 transcript produced by alternative splicing encodes a protein that conserves the transmembrane and cytoplasmic portions but lacks extracellular cysteine residues required for disulfide bonds; transfection studies showed this variant mb-1 does not contribute to BCR surface expression; B cell activation (anti-IgM, LPS, or IL-4) induces significant increases in variant transcript levels.\",\n      \"method\": \"Alternative splicing characterization, transfection assays, B cell activation experiments with anti-IgM/LPS/IL-4\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — transfection reconstitution experiment showing functional null variant, combined with activation-regulated splicing, single lab\",\n      \"pmids\": [\"8747711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Receptor-facilitated antigen presentation requires recruitment of the B cell linker protein (BLNK) to CD79A (Igalpha): non-ITAM tyrosines Y176 and Y204 of Igalpha, when mutated, divert BCR complexes to late endosomes but exclude them from vesicle lumena and prevent antigen presentation to T cells; phosphorylation of Y176/Y204 recruits BLNK, Vav, and Grb2; reconstitution with BLNK rescues antigen presentation and entry into the MHC class II compartment.\",\n      \"method\": \"Site-directed mutagenesis of Igalpha non-ITAM tyrosines (Y176/Y204), antigen presentation assays, subcellular trafficking analysis, reconstitution with BLNK\",\n      \"journal\": \"Journal of immunology (Baltimore, Md.: 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with functional reconstitution and subcellular localization readout, multiple orthogonal assays\",\n      \"pmids\": [\"11859098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD79A non-ITAM tyrosine Y204 becomes phosphorylated upon BCR engagement and mediates a distinct T cell-independent B cell activation pathway: knock-in mice with Y204F mutation show selective defects in T-independent B cell activation, proliferation, and antibody responses with reduced BLNK phosphorylation, Ca2+ flux, and NF-κB/JNK/ERK activation, while BCR capping, antigen internalization, antigen presentation, T cell-dependent responses, and Syk phosphorylation remain normal.\",\n      \"method\": \"Targeted knock-in mutagenesis (Y204F) in mice, B cell activation assays, proliferation assays, Ca2+ flux, kinase phosphorylation analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo knock-in mutagenesis with multiple orthogonal functional readouts establishing a specific signaling pathway\",\n      \"pmids\": [\"16860757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Basal (ligand-independent, tonic) signals mediated through CD79A (Igalpha)/Igbeta cytoplasmic domains expressed as a membrane-targeted surrogate receptor in primary pro-B cells are sufficient to drive pre-BCR-dependent processes: enhanced proliferation at low IL-7, suppression of VH(D)JH recombination, and induction of kappa light chain recombination and expression, demonstrating that pre-BCR aggregation is not required for pre-BCR function.\",\n      \"method\": \"Surrogate receptor construct (membrane-targeted Igalpha/Igbeta cytoplasmic domains) introduced into primary pro-B cells by retroviral transduction; proliferation, VDJ recombination, and kappa chain expression assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md.: 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution approach with surrogate receptor in primary cells, multiple functional endpoints\",\n      \"pmids\": [\"15240688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD79A (Igalpha) tonic signaling through its ITAM and cytoplasmic domain supports development of follicular B cells; chimeric protein analysis with Tyr→Phe modifications and single vs. tandem ITAM copies showed both Igalpha and Igbeta support follicular B cell formation under tonic signaling conditions, but neither marginal zone nor B1 B cell subsets develop under purely tonic signal conditions.\",\n      \"method\": \"Chimeric receptor constructs with Tyr→Phe ITAM modifications, gene transfer into RAG2-/- pro-B cell lines and muMT mice, flow cytometric analysis of B cell subsets\",\n      \"journal\": \"Journal of immunology (Baltimore, Md.: 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis of ITAM tyrosines combined with in vivo gene transfer reconstitution and multi-subset analysis\",\n      \"pmids\": [\"17114463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The CD79A (Igalpha) cytoplasmic domain is dominant over Igbeta for BCR internalization; the internalization signal is located in a region past the first cytoplasmic tyrosine (Y176); a 4-amino-acid motif within the Igalpha ITAM is sufficient to rescue aberrant internalization; each cytoplasmic domain alone is sufficient for trafficking to lysosomal compartments, but normal trafficking rate requires both Igalpha and Igbeta.\",\n      \"method\": \"Expression of Igalpha/Igbeta mutants in Igalpha/Igbeta-deficient murine lymphoid cell line, internalization assays, subcellular localization analysis\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — domain mutagenesis with functional internalization and trafficking readouts, multiple orthogonal mutants tested\",\n      \"pmids\": [\"20837062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-4 markedly upregulates Igα (CD79A) and Igβ protein (but not mRNA) expression in primary B cells via STAT6; elevated Igα/Igβ protein forms heterodimers that associate with IgM, promote IgM maturation and surface IgM expression, and result in amplified Lyn-dependent BCR signaling; in vivo pre-germinal center B cells show IL-4-dependent upregulation of Igα, Igβ, and surface IgM with elevated BCR-triggered phospho-ERK.\",\n      \"method\": \"IL-4 treatment of primary B cells, STAT6 requirement analysis, co-immunoprecipitation of heterodimers with IgM, surface IgM flow cytometry, BCR signaling assays, in vivo neutralization of IL-4\",\n      \"journal\": \"Journal of immunology (Baltimore, Md.: 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (co-IP, signaling assays, flow cytometry) in vitro and in vivo, with genetic validation (STAT6 requirement and anti-IL-4 neutralization)\",\n      \"pmids\": [\"23776171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD79A is unexpectedly expressed on immature bone marrow myeloid cells and is upregulated on myeloid-derived suppressor cells (MDSCs) in mouse models of metastatic cancer; crosslinking CD79A on MDSCs maintained their immature CD11b+Gr1+ phenotype, enhanced migration, increased T cell suppression, and increased pro-tumorigenic cytokine secretion (IL-6, CCL22); CD79A activation on myeloid cells signals through Syk, BLNK, ERK, and STAT3 phosphorylation.\",\n      \"method\": \"CD79A crosslinking with specific antibody on MDSCs, flow cytometry for phenotype, migration assays, T cell suppression assays, cytokine secretion measurement, phosphorylation analysis (Syk/BLNK/ERK/STAT3), in vivo tumor growth assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with crosslinking and signaling readouts, single lab, in vitro and in vivo\",\n      \"pmids\": [\"24146823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRISPR/Cas9 deletion of CD79A (or CD79B) in human B lymphoma cell lines causes loss of surface IgM expression in all tested lines by blocking N-glycan maturation and causing accumulation of immature BCR proteins, consistent with retention in the endoplasmic reticulum; rescue with wild-type CD79B restored surface CD79A and IgM with mature glycosylation, while a naturally occurring CD79B G137S mutant that disrupts CD79A/CD79B heterodimerization failed to rescue, demonstrating that CD79A/CD79B heterodimerization is required for BCR surface expression.\",\n      \"method\": \"CRISPR/Cas9 knockout of CD79A or CD79B in B lymphoma lines, rescue with WT vs. G137S mutant CD79B, N-glycan maturation analysis, surface IgM flow cytometry, ER retention assessment\",\n      \"journal\": \"Journal of immunology (Baltimore, Md.: 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — CRISPR knockout with mechanistic rescue experiments using WT and heterodimerization-defective mutant, multiple cell lines, orthogonal assays\",\n      \"pmids\": [\"36426942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In the avian (chicken) BCR, the cytoplasmic domain of Igalpha (CD79A ortholog) efficiently supports B cell development in precursors lacking endogenous surface Ig expression when expressed as a chimeric CD8α-Igalpha construct; by contrast, an equivalent chimeric construct containing the Igbeta cytoplasmic domain actively inhibited B cell development, demonstrating functionally distinct roles for the two cytoplasmic domains in B cell development.\",\n      \"method\": \"Retroviral gene transfer of chimeric CD8α-Igalpha or CD8α-Igbeta constructs into developing chicken B cell precursors in vivo; analysis of B cell development\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vivo reconstitution in avian model with chimeric constructs, single lab, ortholog study\",\n      \"pmids\": [\"14962183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MHC class II associates with Igα/Igβ (CD79A/CD79B); mutations in the connecting peptide region of the MHC II alpha chain (but not beta chain) impair MHC II-mediated calcium mobilization and abolish co-association with Igα/Igβ, while Igβ knockdown by shRNA eliminates the MHC II-mediated calcium response but not cell death signaling.\",\n      \"method\": \"MHC II alpha chain connecting peptide mutagenesis, co-immunoprecipitation with Igα/Igβ, shRNA knockdown of Igβ, Ca2+ mobilization and cell death assays\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and mutagenesis combined with functional knockdown, single lab, two orthogonal approaches\",\n      \"pmids\": [\"18194817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD79A signaling domain incorporated as a composite CD79A/CD40 co-stimulatory endodomain in CD19 CAR-T cells enhances NF-κB and p38 activation upon CD19 antigen exposure, produces superior T cell proliferation, sustained tumor suppression, and enhanced in vivo anti-tumor activity and CAR-T cell expansion compared to CD28 or 4-1BB co-stimulatory domains in a Raji mouse model.\",\n      \"method\": \"Chimeric antigen receptor T cell engineering with CD79A/CD40 endodomain, NF-κB/p38 signaling analysis, in vitro co-culture cytotoxicity and proliferation assays, in vivo Raji xenograft mouse model\",\n      \"journal\": \"Molecular therapy: the journal of the American Society of Gene Therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — engineered receptor with signaling readouts and in vivo functional validation, single lab\",\n      \"pmids\": [\"33940156\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD79A (Igα/mb-1) is a B-lineage transmembrane glycoprotein that obligatorily heterodimerizes with CD79B (Igβ) to chaperone the B cell receptor (BCR) complex through the endoplasmic reticulum and onto the cell surface; within the BCR, its ITAM tyrosines recruit Syk to initiate signaling, while its non-ITAM tyrosines (Y176/Y204) independently recruit BLNK/Vav/Grb2 to mediate antigen internalization, antigen presentation, and T-independent B cell proliferation; CD79A also provides ligand-independent tonic signals required for B cell development through the pro-B to pre-B checkpoint, is regulated post-translationally by IL-4 via STAT6, undergoes somatic hypermutation in germinal center B cells, and loss-of-function mutations cause a complete block in B cell development resulting in agammaglobulinemia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD79A (Igα/mb-1) is a B-lineage-restricted transmembrane glycoprotein that serves as the signal-transduction component of the B cell antigen receptor (BCR), functioning as the B-cell equivalent of CD3 [#0, #3]. It obligatorily heterodimerizes with CD79B (Igβ), and this heterodimerization is required for maturation of BCR N-glycans, escape from the endoplasmic reticulum, and surface display of IgM; loss of either partner or a heterodimerization-defective CD79B mutant blocks surface BCR expression [#16]. The Igα cytoplasmic domain is both necessary and sufficient to reconstitute Ca2+ flux and phosphorylation responses when fused to a signaling-deficient IgM, establishing it as a self-contained signaling module [#1]. CD79A signaling is functionally partitioned: its ITAM tyrosines drive canonical activation, while the non-ITAM tyrosines Y176 and Y204 are phosphorylated upon BCR engagement and recruit BLNK, Vav, and Grb2 to mediate antigen internalization into the MHC class II compartment for presentation to T cells, and additionally support a distinct T-independent activation pathway feeding NF-κB/JNK/ERK signaling and proliferation [#9, #10]. The Igα cytoplasmic domain is dominant over Igβ for BCR internalization and lysosomal trafficking [#13]. Beyond antigen-driven signaling, ligand-independent tonic signals through the Igα/Igβ cytoplasmic domains drive pre-BCR-dependent processes—proliferation, suppression of VH(D)JH recombination, and induction of kappa light chain expression—and support follicular B cell development [#11, #12]. Consistent with this central role, homozygous loss-of-function mutations in CD79A cause a complete block in B cell development at the pro-B to pre-B transition, producing agammaglobulinemia [#4, #5]. CD79A expression and signaling are further tuned by IL-4, which upregulates Igα/Igβ protein via STAT6 to amplify surface IgM and BCR signaling [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established the molecular identity of CD79A by cloning a B-lineage-restricted surface glycoprotein, defining the entity before any signaling role was known.\",\n      \"evidence\": \"cDNA cloning, sequence analysis, and surface immunostaining across B and non-B cell lines\",\n      \"pmids\": [\"2463161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional or signaling role assigned at cloning\", \"Partner CD79B and BCR association not yet defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Resolved the developmental timing of CD79A relative to CD79B, showing the two BCR signaling components are differentially regulated across B cell differentiation.\",\n      \"evidence\": \"Immunocytochemistry with anti-peptide antibodies on B cell lines, tissues, and leukemias\",\n      \"pmids\": [\"1396979\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Expression timing does not establish signaling function\", \"Single primary method\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrated that the Igα cytoplasmic domain is necessary and sufficient for BCR signal transduction, defining CD79A as the receptor's signaling module rather than a passive structural subunit.\",\n      \"evidence\": \"IgM transmembrane mutagenesis and Igα/Igβ cytoplasmic-domain fusion constructs with Ca2+ flux and phosphorylation readouts\",\n      \"pmids\": [\"7688784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of distinct Igα vs Igβ pathways not enumerated\", \"In vitro/cell-line context only\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Characterized alternatively spliced CD79A transcripts encoding truncated proteins, including a variant lacking extracellular disulfide cysteines that does not support BCR surface expression and is induced by B cell activation.\",\n      \"evidence\": \"RNase protection, cDNA cloning, transfection reconstitution, and anti-IgM/LPS/IL-4 activation assays\",\n      \"pmids\": [\"7643857\", \"8747711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological role of activation-induced variant unresolved\", \"Whether variant acts as a dominant-negative not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified CD79A as genetically required for the pro-B to pre-B checkpoint in humans, linking the BCR signaling module to a defined developmental block and to agammaglobulinemia.\",\n      \"evidence\": \"Genetic screening, B cell developmental immunofluorescence, and V-DJ sequencing in agammaglobulinemia patients, replicated in a second patient\",\n      \"pmids\": [\"10525050\", \"11920841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signal that arrests development not defined\", \"Epistasis only relative to mu-heavy-chain deficiency\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Confirmed CD79A loss-of-function as a recurrent cause of agammaglobulinemia in an independent patient, solidifying genotype-phenotype causality.\",\n      \"evidence\": \"Genetic sequencing and clinical immunological evaluation\",\n      \"pmids\": [\"11920841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method\", \"No functional reconstitution of the specific splice mutation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the non-ITAM tyrosines Y176/Y204 as the adaptor-recruitment platform that routes the BCR for antigen presentation, separating presentation from canonical activation.\",\n      \"evidence\": \"Site-directed mutagenesis of Y176/Y204, BLNK reconstitution, antigen presentation and subcellular trafficking assays\",\n      \"pmids\": [\"11859098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of Vav vs Grb2 not dissected\", \"Structural basis of phospho-tyrosine recognition not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed that ligand-independent tonic signals from the Igα/Igβ cytoplasmic domains alone are sufficient for pre-BCR functions, establishing that receptor aggregation is dispensable for these outputs.\",\n      \"evidence\": \"Membrane-targeted surrogate Igα/Igβ receptor in primary pro-B cells with proliferation, VDJ recombination, and kappa expression readouts; chicken chimeric CD8α-Igα reconstitution\",\n      \"pmids\": [\"15240688\", \"14962183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of tonic signal initiation unknown\", \"Igα and Igβ shown to have opposing effects on development in avian model, mechanism unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Assigned distinct in vivo functions to Igα tyrosine motifs—Y204 to T-independent activation and the ITAM/cytoplasmic domain to follicular B cell development—demonstrating signal partitioning within a single chain.\",\n      \"evidence\": \"Y204F knock-in mice and chimeric ITAM Tyr→Phe constructs with activation, proliferation, Ca2+, kinase, and B cell subset analyses\",\n      \"pmids\": [\"16860757\", \"17114463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why marginal zone and B1 subsets fail to form under tonic signaling not explained\", \"Direct binding partners of Y204 not all defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked CD79A/CD79B to MHC class II signaling, showing Igα/Igβ co-associate with MHC II to mediate calcium responses.\",\n      \"evidence\": \"MHC II alpha-chain connecting-peptide mutagenesis, co-IP with Igα/Igβ, and Igβ shRNA knockdown with Ca2+ and cell-death readouts\",\n      \"pmids\": [\"18194817\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect association of CD79A specifically not isolated from Igβ\", \"Physiological role of MHC II–BCR module unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapped the BCR internalization signal to the Igα cytoplasmic domain, showing it is dominant over Igβ for endocytosis and lysosomal trafficking.\",\n      \"evidence\": \"Igα/Igβ mutant expression in deficient murine lymphoid cells with internalization and subcellular localization assays\",\n      \"pmids\": [\"20837062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endocytic adaptors engaged by the internalization motif not identified\", \"Cell-line context only\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established post-translational control of CD79A by IL-4/STAT6 and uncovered an unexpected non-B-cell role on myeloid-derived suppressor cells.\",\n      \"evidence\": \"IL-4 treatment with STAT6 dependence, co-IP and signaling assays in primary B cells; CD79A crosslinking with Syk/BLNK/ERK/STAT3 readouts and tumor assays on MDSCs\",\n      \"pmids\": [\"23776171\", \"24146823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of CD79A surface display on myeloid cells without a conventional BCR unknown\", \"Myeloid finding from single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the chaperone mechanism: CD79A/CD79B heterodimerization is required for N-glycan maturation and ER export of the BCR, explaining why either subunit's loss abolishes surface IgM.\",\n      \"evidence\": \"CRISPR/Cas9 knockout in B lymphoma lines with WT vs heterodimerization-defective CD79B G137S rescue, N-glycan maturation and surface IgM analyses\",\n      \"pmids\": [\"36426942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Step at which immature BCR is retained in ER not resolved at structural level\", \"Whether human developmental block reflects same trafficking defect not directly tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated translational utility of the CD79A signaling domain as a CAR-T co-stimulatory endodomain, leveraging its NF-κB/p38 activation.\",\n      \"evidence\": \"CD79A/CD40 composite endodomain in CD19 CAR-T cells with signaling, cytotoxicity, and Raji xenograft assays\",\n      \"pmids\": [\"33940156\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Engineered context does not test endogenous CD79A function\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CD79A signaling is repurposed on non-B myeloid cells lacking a conventional BCR, and the structural basis for its differential ITAM vs non-ITAM tyrosine partner selection, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of CD79A in complex with downstream adaptors in the corpus\", \"Mechanism of CD79A surface expression on myeloid cells unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 9, 10]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [9, 13]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 16]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 10, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 9, 10]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 11, 12]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [16, 14]}\n    ],\n    \"complexes\": [\"B cell antigen receptor (BCR) complex\", \"CD79A/CD79B heterodimer\"],\n    \"partners\": [\"CD79B\", \"BLNK\", \"Vav\", \"Grb2\", \"Syk\", \"IgM\", \"Lyn\", \"STAT6\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}